<div id="readability-page-1"><p>Axa S.A. grew its position in shares of  Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 6.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The institutional investor  owned 171,270 shares of the pharmaceutical company's stock after purchasing an additional 10,477 shares during the period. Axa S.A. owned approximately 0.07% of Vertex Pharmaceuticals worth $76,249,000 at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>Vertex Pharmaceuticals</strong> alerts:</span></p></div><ul><li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li></ul><p>Other hedge funds also recently made changes to their positions in the company. Activest Wealth Management purchased a new position in  Vertex Pharmaceuticals during the 1st quarter valued at approximately $25,000.  Clal Insurance Enterprises Holdings Ltd boosted its position in shares of  Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock valued at $27,000 after acquiring an additional 45 shares during the last quarter.  Access Investment Management LLC purchased a new position in shares of  Vertex Pharmaceuticals in the second quarter valued at $27,000.  Flaharty Asset Management LLC bought a new stake in  Vertex Pharmaceuticals in the first quarter worth $32,000.  Finally, Legacy Investment Solutions LLC purchased a new stake in  Vertex Pharmaceuticals during the second quarter valued at $29,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Vertex Pharmaceuticals Trading Down 3.0%</h2><p>NASDAQ:VRTX opened at $442.04 on Tuesday. The company has a market cap of $112.15 billion, a price-to-earnings ratio of 31.17 and a beta of 0.32. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $519.68. The stock has a fifty day simple moving average of $423.07 and a 200-day simple moving average of $425.36. </p><ul><li>Best Biotech Stocks to Buy in 2025</li></ul><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 EPS for the quarter, topping the consensus estimate of $4.58 by $0.22. The company had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. Vertex Pharmaceuticals had a net margin of 31.35% and a return on equity of 23.51%. The firm's revenue was up 11.0% compared to the same quarter last year. During the same quarter last year, the firm posted $4.38 EPS.  As a group, equities research analysts predict that  Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year. </p><h2>Analysts Set New Price Targets</h2><p>VRTX has been the subject of a number of recent research reports. Barclays lifted their price objective on shares of Vertex Pharmaceuticals from $408.00 to $414.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Tuesday, November 4th. Citigroup boosted their price objective on Vertex Pharmaceuticals from $550.00 to $575.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, October 2nd. Leerink Partners upgraded Vertex Pharmaceuticals from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and decreased their price objective for the company from $458.00 to $456.00 in a research report on Thursday, September 25th. JPMorgan Chase &amp; Co. raised their price objective on Vertex Pharmaceuticals from $517.00 to $530.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus cut their target price on Vertex Pharmaceuticals from $455.00 to $445.00 and set a &#34;hold&#34; rating on the stock in a research report on Tuesday, November 4th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and ten have assigned  a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $495.53.</p><ul><li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li></ul><p><b>Read Our Latest Report on VRTX</b></p><h2>Insider Activity at Vertex Pharmaceuticals</h2><p>In other news, EVP Charles F. Wagner, Jr. sold 14,000 shares of the stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $456.00, for a total transaction of $6,384,000.00. Following the transaction, the executive vice president owned 37,725 shares of the company's stock, valued at approximately $17,202,600. This represents a 27.07% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, Chairman Jeffrey M. Leiden sold 63,781 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $449.20, for a total value of $28,650,425.20. Following the completion of the sale, the chairman owned 24,026 shares of the company's stock, valued at $10,792,479.20. The trade was a 72.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 151,073 shares of company stock worth $67,326,816. 0.20% of the stock is owned by insiders. </p><h2>Vertex Pharmaceuticals Company Profile</h2> (Free Report)<p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Vertex Pharmaceuticals</li><li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li><li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li><li>Profitably Trade Stocks at 52-Week Highs</li><li>3 Stocks Most Likely to Split in 2026</li><li>3 Natural Gas Stocks That Offer Great Dividend Yields</li><li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li></ul><p><strong>Want to see what other hedge funds are holding VRTX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

VRTX

<p>Axa S.A. increased its stake in Vertex Pharmaceuticals by 6.5% in Q2, owning 171,270 shares worth $76.25 million. Analysts have set new price targets for Vertex, with Citigroup raising its target to $575 and JPMorgan to $530. The stock has an average rating of "Moderate Buy" with a consensus price target of $495.53. Insider activity includes EVP Charles Wagner selling 14,000 shares.</p>

Axa S.A. Buys 10,477 Shares of Vertex Pharmaceuticals Incorporated $VRTX